3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
127
Kidney Neoplasms
39
Neoplasms
37
Neoplasm Metastasis
35
Breast Neoplasms
33
Gastrointestinal Stromal Tumors
27
Carcinoma, Non-Small-Cell Lung
22
Prostatic Neoplasms
16
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
12
Brain Neoplasms
12
Pancreatic Neoplasms
11
Glioblastoma
11
Carcinoma, Hepatocellular
11
Melanoma
10
Lung Neoplasms
10
Stomach Neoplasms
8
Neuroendocrine Tumors
8
Carcinoma
8
Thyroid Neoplasms
7
Sarcoma
7
Ovarian Neoplasms
7
Multiple Myeloma
7
Liver Neoplasms
7
Small Cell Lung Carcinoma
6
Leukemia, Myeloid, Acute
6
Glioma
6
Esophageal Neoplasms
6
Adenoma, Islet Cell
6
Uveal Melanoma
5
Interventions
lutetium Lu 177 dotatate
6
lanreotide
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
copper dotatate CU-64
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastro-enteropancreatic neuroendocrine tumor
×
Sunitinib
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled